Table 3. Antimicrobial resistance rates (%) of Acinetobacter baumannii and Pseudomonas aeruginosa in Korea from 2013 to 2015*.
| Antimicrobial agent | A. baumannii | P. aeruginosa | ||||
|---|---|---|---|---|---|---|
| 2013 (11,117) | 2014 (10,288) | 2015 (9,345) | 2013 (9,703) | 2014 (6,919) | 2015 (5,259) | |
| Piperacillin | 82 (60–100) | 87 (66–97) | 86 (76–97) | 30 (14–49) | 26 (14–46) | 27 (16–46) |
| Ampicillin-sulbactam | 57 (16–76) | 50 (24–91) | 46 (16–75) | NT | NT | NT |
| Piperacillin-tazobactam | 81 (56–100) | 86 (71–100) | 82 (69–96) | 29 (2–54) | 28 (14–50) | 25 (7–45) |
| Cefotaxime | 79 (56–100) | 86 (71–97) | 84 (65–100) | NT | NT | NT |
| Ceftazidime | 77 (51–93) | 84 (55–97) | 83 (56–96) | 21 (6–39) | 21 (8–37) | 19 (9–40) |
| Cefepime | 78 (55–93) | 85 (70–97) | 83 (67–96) | 20 (6–34) | 20 (7–37) | 18 (6–37) |
| Aztreonam | NT | NT | NT | 23 (13–51) | 33 (10–68) | 23 (13–38) |
| Imipenem | 77 (54–92) | 84 (70–96) | 85 (73–97) | 32 (12–57) | 35 (16–50) | 35 (15–47) |
| Meropenem | 77 (55–93) | 85 (66–96) | 84 (67–96) | 24 (10–46) | 27 (12–40) | 25 (15–45) |
| Amikacin | 45 (3–79) | 52 (12–83) | 60 (8–89) | 13 (4–25) | 12 (6–59) | 13 (6–47) |
| Gentamicin | 73 (42–88) | 76 (52–89) | 75 (42–90) | 19 (7–32) | 20 (7–37) | 18 (5–37) |
| Ciprofloxacin | 84 (59–96) | 88 (74–98) | 87 (75–97) | 36 (15–53) | 30 (20–48) | 34 (17–47) |
| Cotrimoxazole | 74 (43–97) | 75 (58–88) | 64 (52–75) | NT | NT | NT |
| Tigecycline | 5 (0–12) | 2 (1–7) | 4 (0–7) | NT | NT | NT |
| Colistin | < 0.1 (0–2) | < 0.1 (0–1) | < 0.1 (0–1) | 1 (0–5) | 1 (0–9) | < 0.1 (0–3) |
*Antimicrobial resistance rates are presented as median (whole range).
Abbreviation: NT, not tested.